Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
NCT01181258
Completed
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect. The investigators have designed a novel lymphodepleting conditioning regimen followed by infusion of donor-derived natural killer (NK) cells and interleukin-2 (IL-2) for patients with refractory lymphoid malignancies.
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2018
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Register for Updates
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
NCT01043640
Completed
Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cycl... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/09/2018
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Adrenoleukodystrophy (ALD), Krabbe Disease, Metachromatic Leukodystrophy (MLD), Sphingolipidoses, Peroxisomal Disorders
Register for Updates
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
NCT00877006
Completed
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2018
Locations: Teva Investigational Site 165, Tucson, Arizona +127 locations
Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Register for Updates
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
NCT03100877
Withdrawn
This phase I/II trial studies the side effects and best dose of melphalan and total marrow irradiation and how well they work with autologous stem cell transplantation in treating patients with high-risk multiple myeloma. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Total marrow irradiation is a type of radiation therapy and a form of total... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/11/2017
Locations: City of Hope Medical Center, Duarte, California
Conditions: Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Register for Updates
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
NCT00093795
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2017
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +11 locations
Conditions: Breast Cancer
Register for Updates
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
NCT00562965
Terminated
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given with rituximab compared to a defined investigator's choice therapy. Subjects will be randomized to one of these two arms of the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2017
Locations: Facey Medical Group, Mission Hills, California +38 locations
Conditions: Lymphoma, Follicular
Register for Updates
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00667615
Completed
The purpose of this study is to replace a drug with many side effects, procarbazine, with a new novel drug, vorinostat, in a drug combination for the treatment of patients with diffuse large B-cell lymphoma. Vorinostat is the first of a new type of chemotherapy drug, known as a histone deacetylase inhibitor, to be approved by the Food and Drug Administration. It is approved for the treatment of certain lymphomas of the skin. It alters the cancer cell pathway by preventing cancer cells from repro... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
12/07/2017
Locations: Memorial Sloan Kettering Cancer Center @ BaskingRidge, Basking Ridge, New Jersey +4 locations
Conditions: Hodgkin's Disease, Lymphoma
Register for Updates
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
NCT00499122
Completed
RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and re... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
12/06/2017
Locations: University of Miami, Miami, Florida +1 locations
Conditions: Breast Cancer
Register for Updates
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
NCT01106950
Terminated
This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox preparative regimen for the treatment of poor prognosis acute myelogenous leukemia (AML).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Myelogenous, Acute
Register for Updates
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT02118285
Completed
This is a single center phase I trial designed to determine the maximum tolerated dose (MTD) of the oral IDO inhibitor INCB024360 when administered as part of a larger regimen of intraperitoneal (IP) delivery of haploidentical donor NK cells and IL-2 after a non-myeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen for the treatment of recurrent ovarian, fallopian tube, and primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Register for Updates
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
NCT00455312
Completed
Transplantation with stem cells is a standard therapy in many centers around the world. Previous experience with stem cell transplantation therapy for leukemias, lymphomas, other cancers, aplastic anemia and other non-malignant diseases, has led to prolonged disease-free survival or cure for some patients. However, the high doses of pre-transplant radiation and chemotherapy drugs used, and the type of drugs used, often cause many side effects that are intolerable for some patients. Slow recovery... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Dyskeratosis Congenita, Aplastic Anemia
Register for Updates
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
NCT00871689
Terminated
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving interleukin-2 (IL-2, aldesleukin) after transplant m... Read More
Gender:
ALL
Ages:
45 years and below
Trial Updated:
12/03/2017
Locations: University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota
Conditions: Leukemia
Register for Updates